Compare · NAGE vs RGC
NAGE vs RGC
Side-by-side comparison of Niagen Bioscience Inc. (NAGE) and Regencell Bioscience Holdings Limited (RGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAGE and RGC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RGC is the larger of the two at $2.50B, about 9.0x NAGE ($276.4M).
- Over the past year, NAGE is down 70.1% and RGC is down 63.2% - RGC leads by 6.9 points.
- NAGE has hit the wire 17 times in the past 4 weeks while RGC has been quiet.
- NAGE has more recent analyst coverage (1 ratings vs 0 for RGC).
PerformanceNAGE-70.13%RGC-63.23%
2025-07-14+0.00%2026-07-14
- Company
- Niagen Bioscience Inc.
- Regencell Bioscience Holdings Limited
- Price
- $3.36-3.31%
- $5.32+4.62%
- Market cap
- $276.4M
- $2.50B
- 1M return
- -2.04%
- -72.86%
- 1Y return
- -70.13%
- -63.23%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 17
- 0
- Recent ratings
- 1
- 0
Latest NAGE
- Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
- SEC Form 424B5 filed by Niagen Bioscience Inc.
- SEC Form EFFECT filed by Niagen Bioscience Inc.
- Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
- SVP, General Counsel Lopez Carlos Luis was granted 2,314 shares, increasing direct ownership by 103% to 4,565 units (SEC Form 4)
- Chief Financial Officer Pamir Ozan was granted 4,255 shares, increasing direct ownership by 58% to 11,627 units (SEC Form 4)
- Chief Executive Officer Fried Robert N was granted 1,106 shares, increasing direct ownership by 0.10% to 1,060,087 units (SEC Form 4)
- Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
- Niagen Bioscience Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form S-3 filed by Niagen Bioscience Inc.
Latest RGC
- SEC Form 4 filed by Director Lo William Wing Yan Dr
- SEC Form 4 filed by Director Hui Evana Yee Wah
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 424B5 filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited